CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Report for D003643: Death NIH

(Synonyms: Deat, Death, Death,)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug587 CT-scan with minimal invasive autopsy Wiki 0.71

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D016757 Death, Sudden, Cardiac NIH 0.71
D017180 Tachycardia, Ventricular NIH 0.71
D013610 Tachycardia NIH 0.50
D007238 Infarction NIH 0.27
D009203 Myocardial Ischemia NIH 0.20
D020521 Stroke NIH 0.20

Correlated HPO Terms (5)

Name (Synonyms) Correlation
HP:0004756 Ventricular tachycardia HPO 0.71
HP:0001645 Sudden cardiac death HPO 0.71
HP:0001649 Tachycardia HPO 0.50
HP:0001658 Myocardial infarction HPO 0.20
HP:0001297 Stroke HPO 0.20

There are 2 clinical trials

Clinical Trials

1 Increasing Our Understanding of COVID-19: Minimal Invasive Autopsies to Investigate Clinical, Radiological, Microbiological and Histopathological Changes in Deceased COVID-19 Patients

Rationale In a very short time corona virus disease 2019 (COVID-19) has become a pandemic with high morbidity and mortality. The main cause of death is respiratory failure including acute respiratory distress syndrome, however the exact mechanisms and other underlying pathology is currently not yet known. In the current setting of the COVID-19 pandemic complete autopsies seem too risky due to the risk of SARS CoV-2 transmission. Yet, as so little is known, additional histopathological, microbiological and virologic study of tissue of deceased COVID-19 patients will provide important clinical and pathophysiological information. Minimal invasive autopsy combined with postmortem imaging seems therefore an optimal method combining safety on the one hand yet proving significant information on the other. This study aims to determine the cause of death and attributable conditions in deceased COVID-19 patients. This will be performed using post-mortem CT-scanning plus CT-guided MIA to obtain tissue for further histological, microbiological and pathological diagnostics. In addition, the pathophysiology of COVID-19 will be examined by further tissue analysis.

NCT04366882 COVID-19 Procedure: CT-scan with minimal invasive autopsy
MeSH:Death

Primary Outcomes

Description: For each individual patient the cause of death and contributing factors will be assessed. For each individual these diagnoses will be made during a meeting of a multidisciplinary team consisting of at least an infectious diseases physician, a radiologist and a pathologist. On a case to case basis, additional medical specialists can be asked to attend, including an intensive care specialist, a geriatrician and/or a microbiologist. During the meetings, the clinical, radiological, microbiological and histopathological data will be presented to all attending specialists. The final diagnoses will be based on consensus. Outcomes will be reported as proportions with a 95% confidence interval.

Measure: Determination of cause of death and contributing factors based on clinical, radiological, microbiological and histopathological data of the deceased patient

Time: up to one month

Secondary Outcomes

Description: The radiological findings will be systematically scored as absent or present. These findings will be reported as proportions with a 95% confidence interval.

Measure: Detailed description of the postmortem radiological changes induced by COVID-19

Time: up to one month

Description: On the basis of clinical observations at this moment in time correlations will be done between the renal histology findings of the patients with and without renal failure at death as well as between the cardiac histology findings of the patients with and without clinical signs of myocarditis. However, in the light of continuous clinical observations and new insights, this may be expanded in the future. Outcomes will be reported as proportions with a 95% confidence interval.

Measure: Detailed description of the postmortem histopathological changes induced by COVID-19

Time: up to one month

Description: Describe the quantity of viral RNA in the different tissues and relate this to the clinical, radiological and histopathological findings.

Measure: Postmortem quantity of viral RNA

Time: up to one month

Description: Study in detail the disease mechanisms at cellular level (including ACE-2 receptor expression in relation to quantity of viral RNA) in the different tissues.

Measure: Postmortem disease mechanisms at cellular level

Time: up to one month

2 Acute Cardiovascular Events Triggered by COVID-19-Related, Non-infectious Stress The Jordan COVID-9 caRdiovascular Events (JoCORE) Study

The current COVID19 pandemic has afflicted almost the whole globe. The stress related to the pandemic, not the direct virus-related injury, can be potentially associated with acute cardiovascular events due to a large list of physical and psychosocial stresses. This study is a cross sectional study that will enroll patients evaluated during the COVID19 pandemic period for acute cardiovascular events.

NCT04368637 Acute Myocardial Infarction Ventricular Tachycardia Sudden Cardiac Death Stroke, Acute
MeSH:Stroke Myocardial Infarction Tachycardia Tachycardia, Ventricular Death, Sudden, Cardiac Infarction Death
HPO:Myocardial infarction Stroke Sudden cardiac death Tachycardia Ventricular tachycardia

Primary Outcomes

Description: Acute myocardial infarction as diagnosed by ST segment elevation or depression or inverted T wave on 12-lead EKG and elevated levels of cardiac troponins above the 99% of the normal values. A. Acute MI (STEMI and NSTEMI). B. Aborted on non-aborted sudden cardiac death not attributed to a known etiology. C. Sustained or non-sustained ventricular tachy-arrhythmia not attributed to a known etiology. D. ICD shocks. 3. Absence of suspected or confirmed infection with the COVID19 virus. 4. Definite physical or psycho-social stressful trigger appearing in relation to the COVID-19 situation (lock down stress, financial stress, anger, depression, fear, sorrow, death of a significant person, eating binges, smoking binges, physical stress [carrying walking for shopping and carrying excess weights] ..etc) as judged by a unanimous agreement of three investigators in the steering committee.

Measure: Acute cardiovascular event triggered by COVID-19 stress

Time: 4 months

Description: Typical ventricular tachycardia on 12-lead EKG or EKG monitor.

Measure: Ventricular tachycardia

Time: 4 months

Description: acute neurological symptoms of hemiparesis or dysrthria due to brain ischemia proven by computerized tomography or magnatic resonance

Measure: acute stroke

Time: 4 months

Description: Finding an episode of ventricular tachycardia on interrogation of ICD tracing

Measure: Implantable cardioverter defibrillator (ICD) shock

Time: 4 months

HPO Nodes